A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain.

[1]  T. Prisinzano,et al.  Functional Selectivity of Kappa Opioid Receptor Agonists in Peripheral Sensory Neurons , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[2]  L. Bohn,et al.  Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias. , 2015, ACS chemical neuroscience.

[3]  S. Inui.  Nalfurafine hydrochloride to treat pruritus: a review , 2015, Clinical, cosmetic and investigational dermatology.

[4]  B. Roth,et al.  The G Protein–Biased κ-Opioid Receptor Agonist RB-64 Is Analgesic with a Unique Spectrum of Activities In Vivo , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[5]  Akira Yamashita,et al.  к Opioids inhibit tumor angiogenesis by suppressing VEGF signaling , 2013, Scientific Reports.

[6]  R. Curi,et al.  Peripheral kappa and delta opioid receptors are involved in the antinociceptive effect of crotalphine in a rat model of cancer pain , 2013, Pharmacology Biochemistry and Behavior.

[7]  L. Bohn,et al.  Functional Selectivity of 6′-Guanidinonaltrindole (6′-GNTI) at κ-Opioid Receptors in Striatal Neurons* , 2013, The Journal of Biological Chemistry.

[8]  P. Mantyh,et al.  Disease modification of breast cancer–induced bone remodeling by cannabinoid 2 receptor agonists , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  P. Wysocki,et al.  Progress in the treatment of bone metastases in cancer patients , 2012, Expert opinion on investigational drugs.

[10]  M. Caron,et al.  Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. , 2012, ACS chemical neuroscience.

[11]  H. Okano,et al.  Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells , 2012, British Journal of Cancer.

[12]  Seongheon Lee,et al.  The Intrathecally Administered Kappa-2 Opioid Agonist GR89696 and Interleukin-10 Attenuate Bone Cancer–Induced Pain Through Synergistic Interaction , 2011, Anesthesia and analgesia.

[13]  Jiyang Ren,et al.  Contribution of afferent pathways to nerve injury-induced spontaneous pain and evoked hypersensitivity , 2011, PAIN.

[14]  J. Fichna,et al.  The role of morphine in regulation of cancer cell growth , 2011, Naunyn-Schmiedeberg's Archives of Pharmacology.

[15]  B. Ferrell,et al.  The management of cancer pain , 2011, CA: a cancer journal for clinicians.

[16]  A. Cress,et al.  Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain , 2011, Molecular pain.

[17]  T. King,et al.  Transient inflammation-induced ongoing pain is driven by TRPV1 sensitive afferents , 2011, Molecular pain.

[18]  James B. Thomas,et al.  The Effect of &kgr;-Opioid Receptor Agonists on Tetrodotoxin-Resistant Sodium Channels in Primary Sensory Neurons , 2009, Anesthesia and analgesia.

[19]  F. De Conno,et al.  Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  C. Svensson,et al.  Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced pain , 2008, Pharmacology Biochemistry and Behavior.

[21]  E. Mascha,et al.  Anesthetic Technique for Radical Prostatectomy Surgery Affects Cancer Recurrence: A Retrospective Analysis , 2008, Anesthesiology.

[22]  Y. Long,et al.  LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential. , 2008, European journal of pharmacology.

[23]  R. Houghten,et al.  Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors. , 2008, European journal of pharmacology.

[24]  A. Cress,et al.  Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer , 2007, Pain.

[25]  M. Bruchas,et al.  Long-Acting κ Opioid Antagonists Disrupt Receptor Signaling And Produce Noncompetitive Effects By Activating C-Jun N-Terminal Kinase* , 2007, Journal of Biological Chemistry.

[26]  E. Mascha,et al.  Can Anesthetic Technique for Primary Breast Cancer Surgery Affect Recurrence or Metastasis? , 2006, Anesthesiology.

[27]  T. Delorey,et al.  Pharmacological profiles of opioid ligands at Kappa opioid receptors , 2006, BMC pharmacology.

[28]  A. Lastra,et al.  Effects of the local administration of selective μ-, δ-and κ-opioid receptor agonists on osteosarcoma-induced hyperalgesia , 2005, Naunyn-Schmiedeberg's Archives of Pharmacology.

[29]  E. Butelman,et al.  Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors , 2005, Psychopharmacology.

[30]  P. Rivière,et al.  FE200041 (d-Phe-d-Phe-d-Nle-d-Arg-NH2): A Peripheral Efficacious κ Opioid Agonist with Unprecedented Selectivity , 2004, Journal of Pharmacology and Experimental Therapeutics.

[31]  N. Wong,et al.  The Overexpression of Bcl‐2 Antagonizes the Proapoptotic Function of the Kappa‐Opioid Receptor , 2003, Annals of the New York Academy of Sciences.

[32]  C. Chavkin,et al.  κ Opioid Receptor Antagonism and Prodynorphin Gene Disruption Block Stress-Induced Behavioral Responses , 2003, The Journal of Neuroscience.

[33]  J. Lameh,et al.  Activity of opioid ligands in cells expressing cloned mu opioid receptors , 2003, BMC pharmacology.

[34]  J. Eisenach,et al.  Analgesia from a peripherally active κ-opioid receptor agonist in patients with chronic pancreatitis , 2003, Pain.

[35]  J. Lameh,et al.  Activation profiles of opioid ligands in HEK cells expressing δ opioid receptors , 2002, BMC Neuroscience.

[36]  L. Bohn,et al.  Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade. , 2001, Journal of neurochemistry.

[37]  L. Bohn,et al.  Mitogenic Signaling via Endogenous κ‐Opioid Receptors in C6 Glioma Cells , 2000 .

[38]  N. Mello,et al.  Effects of kappa opioids on cocaine self-administration by rhesus monkeys. , 1997, The Journal of pharmacology and experimental therapeutics.

[39]  J. M. Ree,et al.  κ-Opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice , 1997 .

[40]  S. D. Glick,et al.  Kappa opioid inhibition of morphine and cocaine self-administration in rats , 1995, Brain Research.

[41]  T. Yaksh,et al.  Quantitative assessment of tactile allodynia in the rat paw , 1994, Journal of Neuroscience Methods.

[42]  D. Scopes,et al.  A potent new class of kappa-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines. , 1993, Journal of medicinal chemistry.

[43]  B. Vonderhaar,et al.  Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. , 1990, Cancer research.

[44]  T. Prisinzano,et al.  Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse. , 2014, Advances in pharmacology.

[45]  W. Dixon,et al.  Efficient analysis of experimental observations. , 1980, Annual review of pharmacology and toxicology.